Literature DB >> 15777845

Blockade of murine erythroleukemia cell differentiation by hypomethylating agents causes accumulation of discrete small poly(A)- RNAs hybridized to 3'-end flanking sequences of beta(major) globin gene.

Ioannis S Vizirianakis1, Asterios S Tsiftsoglou.   

Abstract

Induction of murine erythroleukemia (MEL) cell differentiation is accompanied by transcriptional activation of globin genes and biosynthesis of hemoglobin. In this study, we observed cytoplasmic accumulation of relatively small RNAs of different size (150-600 nt) hybridized to alpha1 and beta(major) globin DNA probes in MEL cells blocked to differentiate by hypomethylating agents (neplanocin A, 3-deazaneplanocin A and cycloleucine). These RNAs lack poly(A) tail and appear to be quite stable. Search within the 3'-end flanking sequences of beta(major) globin gene revealed the presence of a B1 repeat element, several ATG initiation codons, a GATA-1 consensus sequence and sequences recognized by AP-1/NF-E2 and erythroid Krüppel-like factor (EKLF) transcription factors. These data taken together indicate that exposure of MEL cells to hypomethylating agents promotes accumulation of relatively small discrete RNA transcripts lacking poly(A) tail regardless of the presence or absence of inducer dimethylsulfoxide (DMSO). However, the relative steady-state level of small RNAs was comparatively higher in cells co-exposed to inducer and each one of the hypomethylating agents. Although the orientation of these RNAs has not been established as yet, the possibility these small poly(A)- RNAs which are induced by hypomethylating agents may be involved in the blockade of MEL cell differentiation program is discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15777845     DOI: 10.1016/j.bbamcr.2004.09.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Pharmacological Development of Target-Specific Delocalized Lipophilic Cation-Functionalized Carboranes for Cancer Therapy.

Authors:  Eirini D Tseligka; Aikaterini Rova; Elsa P Amanatiadou; Gianpiero Calabrese; John Tsibouklis; Dimitrios G Fatouros; Ioannis S Vizirianakis
Journal:  Pharm Res       Date:  2016-04-26       Impact factor: 4.200

2.  miR-16-5p Promotes Erythroid Maturation of Erythroleukemia Cells by Regulating Ribosome Biogenesis.

Authors:  Christos I Papagiannopoulos; Nikoleta F Theodoroula; Ioannis S Vizirianakis
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-09

3.  The histone methyltransferase inhibitor A-366 enhances hemoglobin expression in erythroleukemia cells upon co-exposure with chemical inducers in culture.

Authors:  Christos I Papagiannopoulos; Nikoleta F Theodoroula; Konstantinos A Kyritsis; Melpomeni G Akrivou; Maria Kosmidou; Konstantina Tsouderou; Nikolaos Grigoriadis; Ioannis S Vizirianakis
Journal:  J Biol Res (Thessalon)       Date:  2021-01-06       Impact factor: 1.889

4.  Novel Thiazolidin-4-ones as Potential Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase.

Authors:  Anthi Petrou; Phaedra Eleftheriou; Athina Geronikaki; Melpomeni G Akrivou; Ioannis Vizirianakis
Journal:  Molecules       Date:  2019-10-23       Impact factor: 4.411

5.  NGIWY-Amide: A Bioinspired Ultrashort Self-Assembled Peptide Gelator for Local Drug Delivery Applications.

Authors:  Nikoleta F Theodoroula; Christina Karavasili; Manos C Vlasiou; Alexandra Primikyri; Christia Nicolaou; Alexandra V Chatzikonstantinou; Aikaterini-Theodora Chatzitaki; Christos Petrou; Nikolaos Bouropoulos; Constantinos K Zacharis; Eleftheria Galatou; Yiannis Sarigiannis; Dimitrios G Fatouros; Ioannis S Vizirianakis
Journal:  Pharmaceutics       Date:  2022-01-06       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.